Oral Otezla (apremilast) long-term safety and efficacy data in patients with moderate to severe plaque psoriasis presented

Celgene Corporation has announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast) were presented at the 73rd...